Axsome Therapeutics Announces FDA Acceptance of New Drug Application for AXS-12 for the Treatment of Cataplexy in Narcolepsy

Go back to Axsome Therapeutics Announces FDA Acceptance of New Drug Application for AXS-12 for the Treatment of Cataplexy in Narcolepsy
(NASDAQ: AXSM) Delayed: 203.10 -2.39 (1.16%)
Previous Close $205.49    52 Week High $15.74 
Open $205.68    52 Week Low $5.37 
Day High $207.01    P/E N/A 
Day Low $202.52    EPS $0.00 
Volume 299,775